BRIEF — Cue Biopharma Announces Positive Topline Results From Cue — 221 Phase 2 Study In Chronic Spontaneous Urticaria
Sept 20 (Reuters) — Cue Biopharma, Inc.: Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria Cue Biopharma, - Phase 2 Primary And Key Secondary Endpoints Met Source text:... Further company coverage: CUE.O (Reuters.Briefs@thomsonreuters.com;)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.